Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UPDATE: Galmed Pharma (GLMD) Reports Q2 Loss of $0.17
August 2, 2018 7:47 AM EDT(Updated - August 2, 2018 7:48 AM EDT)
Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS Loss of $0.17, versus ($0.16) reported last year. Revenue for the quarter came in at $270 thousand versus the consensus estimate of $270 thousand.
Financial Summary - First Quarter 2018 vs. First Quarter 2017:
Cash and cash equivalents and marketable securities totaled $94.1 million as of June 30, 2018, compared to $19.0 million at December 31, 2017. The increase is mainly... More